September 10 - Challenging Barriers: Broader Treatment Options
By Ann M. Palmer, President and CEO, Arthritis Foundation National Office
Issues of advocacy and access have long been a priority of the Arthritis Foundation. But there is a renewed sense of urgency as we shape our expanded vision of what it means to be an effective and powerful patient advocacy organization and a successful voice on issues of importance to our constituents—the more than 50 million Americans living with arthritis.
Patients and physicians are raising increasingly urgent concerns regarding timely access to a full range of treatment options and we are a strong voice in fighting against overly restrictive pharmacy plans and processes that can delay or even prevent a patient from receiving life-changing medication.
A couple of months ago, I wrote a letter to the medical director of Medical Mutual of Ohio, expressing concern and requesting a change to the company’s new Recommended Authorization Criteria requiring the use of a Preferred Drug, i.e., the injectable TNF antagonist medications, prior to the use of an infusible TNF antagonist agent.
I explained that the Arthritis Foundation advocates for:
- Access to the full range of treatment for all people with all types of arthritis, including inflammatory types such a rheumatoid arthritis;
- Supports access to a full range of treatment options, including various forms of administration; and
- Supports the physician’s right to choose the appropriate therapy for his or her patients, and we are opposed to any policy that interferes with the medical decision-making process of the doctor-patient relationship. The choice of therapy is complex and should be determined by the physician based on a number of variables, both medical and patient-centric. These variables include the diagnosis, disease characteristics, prognosis and physician’s clinical judgment and experience, as well as factors such as the patient’s proximity to the physician’s office, mobility and functional limitations.
Medical Mutual of Ohio responded quickly and favorably to my inquiry, agreeing to broaden the range of treatments and, as a result, beginning September 1, 2014, the medical benefit requirement that a trial of a self-administered anti-tumor necrosis factor-alpha agent be attempted prior to treatment with Remicade® was eliminated.
This expansion of treatment options is a win for the millions of people with an inflammatory form of arthritis in Ohio. However, it is not a complete victory, as many viable treatment options are still not included. As we know, people respond differently to the different treatments for inflammatory arthritis and need to have their options open so that they can find the right medication for them.
Because of this, I am continuing the dialogue with Medical Mutual of Ohio to request that they consider broadening their coverage to ensure that there is a complete access to appropriate treatments for all people with inflammatory arthritis in Ohio. I will keep you posted on the results.
Ann M. Palmer
President and CEO, Arthritis Foundation
August 27 - Access to Medication Bill Signed in Illinois
Illinois Governor Pat Quinn has signed into law House Bill 3638 that was actively supported by the Arthritis Foundation. The new law, which takes effect on January 1, 2015, will provide better access to medications and better information about health insurance coverage of medications for people with arthritis
The law will streamline the prior authorization approval time to no more than 72 hours or 24 hours in cases of an expedited coverage determination. It will also require health insurers to provide information on their websites to allow consumers to compare the treatment of medications. Consumers would be provided information about the covered prescription drugs, tiering and the cost-sharing structure for each tier and information about how a consumer can obtain specific copayment amounts or coinsurance percentages for a specific plan before enrolling in that plan.
August 22 - Arthritis Foundation Sends Biosimilar Naming Letter to FDA
Click here to read the letter sent by Arthritis Foundation President and CEO, Ann M. Palmer, to the U.S. Food and Drug Administration on the biosimilar naming issue.
August 5 - The Arthritis Foundation filed comments with the Idaho Board of Pharmacy on proposed rules regarding the substitution of biosimilar drugs for biologics.
The comments stated, “This rule allowing pharmacists to unilaterally substitute a biosimilar therapy for a prescribed reference biologic disrupts the patient-physician relationship, undermines physician judgment and clinical experience and, more importantly, puts patient outcomes and safety at risk. The proposal also does not require a pharmacist to notify the prescriber of any substitution.
July 21 - Arthritis Foundation recognized for its advocacy work to enact legislation in Connecticut that will curtail medication “step therapy”
Click here to read an article from HartfordBusiness.com, a publication by the Hartford Business Journal.
July 17 - Read the Advocacy in Action Newsletter
July 10 - Arthritis Foundation Asks Medicare to Stop Putting Patient Care at Risk
When the Arthritis Foundation learned that CMS was making decisions about which medications they would reimburse for based on the method of administration, Ann Palmer the AF CEO wrote this letter outlining the importance of having all forms of a drug available to arthritis patients.
July 1 - Check Out the Latest Edition of Advocacy in Action!
June 24 – Pennsylvania Moves Closer to Allowing Biosimilars
The Pennsylvania Senate passed Senate Bill 405 by a vote of 44-6 to allow the substitution of biosimilars for biologic medicines. Arthritis Foundation representatives visited the legislature the day before the Senate vote to help secure the bill’s passage. A great victory for our Ambassadors and Advocates!
June 24 – New Massachusetts Law to Allow for New Treatments for Arthritis
The Arthritis Foundation thanked Massachusetts Governor Deval Patrick for his enactment of House Bill 3734 that permits the use of biosimilar medications. The Arthritis Foundation has been a critical part of the consideration of this legislation by providing testimony, written position statements and a letter of support urging the Governor to sign the bill.
June 10 - Letter Sent to Medical Mutual of Ohio
Arthritis Foundation President and CEO, Ann M. Palmer, sent a letter to Medical Mutual of Ohio to ensure access to vital medications for people with arthritis. To read the letter, please click here.
Connecticut Legislation Signed into Law
Connecticut Governor Dannel P. Malloy (center) signs legislation (Senate Bill 394) regulating “Insurers’ Use of Step Therapy” into law in front of patient advocates, including Arthritis Foundation Regional Advocacy Committee Chair Paula Haney (third from left).
June 6 – Putting Arthritis Medicine Decisions Back in the Hands of Doctors
The Arthritis Foundation has been working to ensure that people with arthritis have access to vital, life-improving treatments.
Because of our efforts including written and in-person testimony before the Senate Insurance Committee and an Op-Ed in the Connecticut Mirror, Connecticut Governor Dannel Malloy signed Senate Bill 394 into law to bar health insurers that use step therapy protocols from requiring their use for more than 60 days and providing doctors with a method to override the protocol.
The act requires insurers to establish and disclose to their providers a process by which the provider may request, at any time, an override of any step therapy regimen. The override process must be convenient for providers to use. At the end of the step therapy period, the act allows an insured's treating health care provider to determine that the step therapy regimen is clinically ineffective for the insured. At that point, the insurer must authorize dispensation of and coverage for the drug prescribed by the provider, if it is covered under the insurance policy or contract.
The law also expands the prohibition on insurer requirements to obtain prescription drugs from a mail order pharmacy. The law extends the scope of the law to cover (1) all other types of insurance entities covering prescription drugs; (2) insurance contracts as well as policies; and (3) policies and contracts that are delivered, renewed, amended, or continued.
The law will become effective on January 1, 2015.
June 4 – Louisiana Monthly Co-Pays Capped at $150 Maximum Per Medicine as of January 1, 2015 and Provides a Specialty Tier Override
Under a new law advocated by the Arthritis Foundation and signed by Louisiana Governor Bobby Jindal, the maximum co-payment or coinsurance for up to a 30-day supply of any single drug may not exceed $150 per month beginning January 1, 2015.
The co-pay limit will become effective once any applicable deductible is reached and until the individual's maximum out-of-pocket limit has been reached.
New law also provides a method for physicians, at the request of patients, to have specialty tier medications included the covered formulary. Under such a request, a non-formulary specialty drug could be deemed covered under the formulary if the prescribing physician determines that the formulary drug for treatment of the same condition either would not be as effective for the individual, would have adverse effects for the individual, or both.
May 28, 2014 – Delaware Biosimilar Substitution Law May Permit Some Lower Cost Arthritis Medications
Delaware Governor Jack Markell signed into law the Arthritis Foundation supported Senate bill 118 that allows pharmacists to substitute interchangeable biosimilars. The hope is that bio-similars will provide patients with lower cost alternatives to biologic drugs.
May 5, 2014 – New Arthritis Foundation Supported Law in Maryland Caps Out-of-Pocket Drug Costs
The Arthritis Foundation helped enact a new law in Maryland that caps out-of-pocket drug costs. House Bill 761 – which limits co-pays and co-insurance on “Specialty Drugs” to a maximum of $150 per 30-day supply, will benefit many of the state’s 1.08 million patients with arthritis. The bill was signed into law by Governor O’Malley and applies to all insurance policies, contracts and health benefit plans issued, delivered, or renewed in Maryland on or after January 1, 2016.
H.R. 460 & H.R. 1827 – Supported by over 25% of the House of Representatives-Arthritis Foundation Advocates Help Add Co-Sponsors to Beneficial Federal Legislation
Through the work of our dedicated Ambassadors and E-Advocates, 33 new co-sponsors have been added to H.R. 460, the “Patients' Access to Treatments Act” since the 2014 Advocacy Summit. The new co-sponsors bring the total to 127 members of the US House of Representatives.
This is an important milestone because H.R. 460 is now co-sponsored by more than one-quarter of the entire U.S. House of Representatives (109 were needed to hit one-quarter). The bill would limit co-payments for specialty tier drugs.
The list of co-sponsors on H.R. 1827, the “Pediatric Subspecialty and Mental Health Workforce Reauthorization Act”, has also increased by 12 (a 35% increase since the Summit) bringing the current roster to 46. The bill seeks to address the nationwide shortage of pediatric subspecialists including rheumatologists.
If your member of the U.S. House of Representatives has not yet signed on as a co-sponsor of these bills, please contact and encourage them to take a stand for patients with arthritis. Your member of Congress may be reached (even if you don’t know who it is) through the Capitol switchboard at (202) 224-3121.
A list of the co-sponsors of H.R. 460 may be found here.
A list of the co-sponsors of H.R. 1827 may be found here.
Department of Defense Includes Arthritis Peer Reviewed Medical Research Program in FY2014
The Department of Defense announced that “post traumatic osteoarthritis” and “rheumatoid arthritis” will be included in the Department of Defense Peer Reviewed Medical Research Program for FY2014. This program awards grants to researchers to look at various diseases affecting our soldiers. This year, over $200 million will be available to the diseases listed in the provision.
Active duty soldiers and veterans have twice the rate of OA when compared to non-military populations, thus the need for research at the Department of Defense is vital. Not only will this benefit our service members, but a breakthrough in research will benefit all with arthritis. Thank you to all of our advocates who called on their Members of Congress to include this important provision in the appropriations bill!
Arthritis Foundation Continues to Monitor Health Benefits
March 20, 2014 – The Arthritis Foundation is continuing to monitor changes to health plans and pharmacy formularies that impact your access to the treatments you need. We need to hear from you too! Read more.
Arthritis Foundation Confirms Drug Access for Express Scripts Customers
January 13, 2014 – Discussions at the end of the year between Arthritis Foundation CEO Ann M. Palmer and Express Scripts, a leading pharmacy benefit management company, led to clarification of the company’s general formulary policies....Read more.
2013 Year End Report
Our advocates had a banner year in 2013! Thanks to the hard work and dedication of our advocates, we were able to have a highly successful year in 2013. Click here for a recap of our activities!
Letter to Express Scripts on Drug Exclusions
December 13, 2013 - Arthritis Foundation CEO Ann M. Palmer sent a letter to Express Scripts concerning access to certain drugs for arthritis patients. The Arthritis Foundation is committed to ensuring that patients receive medically important drugs that could be successful in treating and managing their inflammatory arthritis. Please click here to read the letter.
Advocates Successful in Keeping Biologic Drugs Accessible
October 23, 2013 - Three weeks ago, advocates were sent an email requesting them to email Marilyn Tavenner, the administrator of the Centers for Medicare and Medicaid. In some states Medicare carriers were making critical biologic drugs impossible for patients to access. Following that outreach, CMS directed the carriers to stop refusing infusions and start putting patients first. Several contractors have already made the changes to their policies reinstating coverage for these biologic therapies. The Arthritis Foundation, in coordination with the American College of Rheumatology, will continue working with the regional contractors to ensure the patient-provider relationship remains a priority.
Ms. Tavenner responded because nearly 2,500 Arthritis Advocates took action. Amidst a government shutdown, Ms. Tavenner took the time to stand up for patients living with arthritis.
MapRX Coalition Guide to Medicare 2014 Part D Open Enrollment
October 18, 2013 - The Arthritis Foundation is an active member of the MapRx Coalition and they have released this document, which addresses many common questions Medicare beneficiaries may have when signing up for Medicare Part D. This document will guide you through the upcoming changes and answer your questions on what you need to know. All Medicare Part D plans are changing and taking the time to review the document and compare plans will help you find the plan that best meets your needs.
Public Health Policy and Advocacy Team Delivers Jingle Bell Run Cheer to Congress on World Arthritis Day
October 11, 2013 - The Public Health Policy and Advocacy Team celebrated World Arthritis Day by hand-delivering squishy snowman stress relievers to 541 legislators and their staff. The team also invited legislators to attend a local Jingle Bell Run / Walk. The message that arthritis impacts everyone, regardless of political party, was well received!
Arthritis Industry Forum Held in Washington, DC
October 7, 2013 - The Arthritis Foundation recently convened its fifth Arthritis Industry Forum in Washington, D.C. that brought together 48 industry stakeholders who represented 19 organizations. This year’s event was moderated by Jamie Glonek, Senior Director of US government relations at Pfizer and chair of the Arthritis Industry Forum. The 2013 industry members included representatives from pharmaceutical, biotech and device companies as well as arthritis advocates who shared their personal stories of how they live with arthritis.
Held each year in October, the Arthritis Industry Forum provides a rare opportunity for unfiltered discussions among stakeholders who examine ideas on how industry and the Foundation can collaborate and advance legislative policy in Washington that focuses on the prevention, control and cure of arthritis. This year’s topics included the health insurance marketplace, ways by which patient health data can grow and impact health care and how the Arthritis Industry Forum can work collectively to advance medicine.
Announcing 2013 Advocacy Leadership Awards
The Public Health Policy and Advocacy Department is pleased to announce Amy Barron, of Cincinnati, Ohio, as this year’s Edward M. Kennedy Advocacy Leadership Award winner. The Edward M. Kennedy Advocacy Leadership award is given to a person who has demonstrated advocacy leadership at local Arthritis Foundation events, builds relationships with state and / or federal legislators, and effectively, passionately works to raise awareness about arthritis and the Arthritis Foundation’s advocacy priorities.
Amy has spent countless hours building relationships with her Members of Congress. She has also served as a patient reviewer for the Congressionally Directed Medical Research Program (CDMRP) at the Department of Defense and for the Patient Centered Outcomes Research Institute (PCORI). Amy currently serves as the National Walk Mission Chair, bringing National and Local walk committees training and resources to ensure the mission of the Arthritis Foundation remains center-stage at all Arthritis Walks. She is also an active Arthritis Ambassador. Her numerous accomplishments are much to be celebrated and we thank her for all she has done for the Foundation.
The Emerging Leader in Advocacy Award is given to a young individual who has demonstrated public service and advocacy on behalf of those impacted with arthritis in their community. The Emerging Leader in Advocacy Award winner is Katherine Herrmann of Harrison, Ohio. Katherine has spent time recruiting e-advocates at local walks and events, becoming the “Face of Arthritis” for Cincinnati Children’s Hospital, and building relationships with her local Members of Congress. Her dedication to advocacy truly makes Katherine a leader and we thank her for her service.
Congratulations to our two winners!
Coalition for Accessible Treatments Holds Senate Briefing
On September 19th, The Coalition for Accessible Treatments held a Congressional briefing in the Senate releasing the results of a new impact study to gain support for the Patients’ Access to Treatments Act. The study can be found here. Patience White, MD, MA, Vice President of Public Health Policy and Advocacy at the Arthritis Foundation, spoke of the challenges that physicians and patients face by the high cost of essential medications. Millions of Americans with chronic, disabling, life-threatening diseases rely on specialty tier drugs and this bill will assist in lowering the cost, making the medications more accessible. Linda Landa, an advocate for the Crohn’s and Colitis Foundation of America spoke about her young son Jacob and how biologics are essential for him to have mobility and be an active teenager. Without the drugs, her son would be unable to attend school with his classmates or pursue his passion of snowboarding. The Senate needs a bill sponsor in order to push this critical legislation forward. To contact your Senator on this important issue, please visit www.senate.gov. To learn more about the Patients’ Access to Treatments Act, please visit our webpage.
Support the Patients' Access to Treatments Act
Performing simple tasks with a rheumatic disease can be impossible. Paying for treatment shouldn’t be. Rheumatic diseases affect over 11 million Americans of all ages. For many, access to specific medication is the only way to prevent disability and ensure quality of life. These life-saving treatments are increasingly being moved to a more expensive ‘Fourth Tier,’ that can add between $12,000 and $48,000 in out of pocket costs to each patient’s treatment every year.
Supporting the Patients' Access to Treatments Act (H.R. 460) will enable access to critical treatments that allow patients to lead a normal life and prevent disability.
A new study shows H.R. 460 would have a negligible impact on insurance premiums.
- View the full study here.
- Read press release from the Coaltion for Accessible Treatments.
- Learn more about the Patients’ Access to Treatments Act by clicking here.
- Media Contact: Carol Galbreath at firstname.lastname@example.org
- Legislative Contact: Maria Spencer at email@example.com
Congressman Mike Doyle is Joining the Fight Against Arthritis
Congressman Mike Doyle (D-PA) has made a video in support of Arthritis Foundation policy initiatives. See below for the video:
Dr. White Featured in The Washington Post
The Washington Post article quotes the Arthritis Foundation’s Dr. White, where she raises awareness about osteoarthritis and what measures can be taken to help manage it and perhaps control it or stop its progression. She notes that weight management and exercise are crucial in accomplishing this, and she also highlights how even small weight loss can produce dramatic results by reducing overall pressure on one’s joints.
Runners are not giving themselves arthritis
By Christie Aschwanden, Published: August 12, The Washington Post
While out on a run recently, I passed a hiker on the trail. “My knees hurt just watching you,” he told me, shaking his head. It was a variation on a comment I hear over and over: Keep running like that, and you’ll give yourself arthritic knees.
The notion that running causes wear and tear on the joints that could spur arthritis makes some intuitive sense. But is it true?
No — if anything, running probably offers protection from osteoarthritis, says Paul Williams, an exercise scientist at Lawrence Berkeley National Laboratory who leads the National Runners’ Health Study and the National Walkers’ Health Study. These projects have enlisted almost 90,000 runners and walkers and followed them since the studies began, in 1991 and 1997, respectively. In an analysis recently published in the journal Medicine & Science in Sports & Exercise, Williams calculated rates of osteoarthritis and hip replacement among participants in his studies and found that runners were approximately half as likely as walkers to develop osteoarthritis or need a hip replacement. Furthermore, runners who ran the most had the lowest risk of osteoarthritis.
“There’s a perception out there that somehow you’re wearing out your joints if you’re out there running,” Williams says, but the thousands of runners in his study show this just isn’t so. “I’ve recruited people who were doing 60 or 70 miles per week, and we’ve followed them over time,” he says. “If there had been an effect, we would have seen it.”
The notion that running causes osteoarthritis arises from a misperception about how joints work, says Alex Hutchinson, a science journalist who is author of the Sweat Science blog at Runner’s World and the book “Which Comes First, Cardio or Weights? Fitness Myths, Training Truths, and Other Surprising Discoveries from the Science of Exercise.” “People think the joint is just a static, inert hinge that wears down, but it’s actually a dynamic, living thing that can respond to stress and adapt and get stronger,” he says. Rather than wear down cartilage and other joint tissue, running appears to strengthen them, Hutchinson says.
The latest research shows that osteoarthritis isn’t just a result of wear and tear on your joints, says Patience White, vice president for public health policy and advocacy at the Arthritis Foundation. Instead, the disease arises from an interplay between environment and genetics. The strongest risk factors for osteoarthritis are obesity and family history, says White, who is also a professor or medicine and pediatrics at the George Washington University School of Medicine and Health Sciences.
Every extra pound you carry is akin to four pounds on your knees, White says: “If you lose five pounds, that’s like 20 pounds across your knees.” But obesity’s role in osteoarthritis isn’t confined to the extra stress it can put on joints. “People who weigh more also get more osteoarthritis in their wrists, so it’s not just about mechanical loading through the joint,” Hutchinson says. Fat tissue is metabolically active and secretes inflammatory hormones that interact with everything in the body, including cartilage and joints, he says.
Family history is another predictor of osteoarthritis, and researchers have identified several genes associated with a susceptibility to the disease. “If you have osteoarthritis in your family, you’re more likely to get it no matter what you do,” White says.
This sounds like bad news for me, since osteoarthritis runs in my family, and my dad recently had a hip replacement because of the disease. But White says I can delay or perhaps even prevent getting osteoarthritis by staying active and keeping my weight in check. Running accomplishes both.
Still, it’s important to run wisely, White says. If you try to go from the couch to a marathon without putting in the necessary training, you’re liable to get hurt. Injury ups the risk of osteoarthritis, although developing the disease takes the kind of traumatic injury that tears ligaments or tendons — problems that more commonly occur in sports that involve contact or require sudden changes in direction. Such injuries increase osteoarthritis risk by promoting abnormal mechanics or by creating scarring that can strain the joint, White says, and an injury can deliver a double whammy by forcing a decrease in physical activity that leads to weight gain.
More than 50 percent of people who have a serious knee injury such as a ligament or tendon tear will develop osteoarthritis within 10 years, White says. “If you’ve had a bad knee injury at age 15, chances are you’ll have osteoarthritis at 25.”
While running wasn’t associated with osteoarthritis in the Williams study, other types of exercise, such as soccer and hockey, were linked with a greater risk of developing the disease. “We’re trying to pursue that further,” Williams says.
Given that other activities seem to increase osteoarthritis risk, why does running get a bad rap? Some of it may be schadenfreude, Hutchinson says. “Every time a runner gets osteoarthritis in their knee, all their friends and family say, ‘See? I told you you shouldn’t have run. You did this to yourself,’ ” he says. “But when five non-runners get osteoarthritis, people just say, ‘Well, I guess you’re getting old.’ ”
I am getting older, and even after decades of running, my knees feel better now than they did when I was 20. I hope I never have to quit trail running, and Williams says that if I keep at it, chances are good that I won’t have to stop anytime soon.
Senate Appropriations Committee Approves Pediatric Subspecialty Loan Repayment Funding
Last Thursday, the Senate Appropriations Committee approved a spending bill for FY 2014 that, for the first time, provides resources to a student loan forgiveness program for pediatric rheumatologists willing to provide care in underserved areas. To achieve this goal, Arthritis Advocates sent over 2,000 messages to the Senate requesting their support and Arthritis Ambassadors worked with key, influential Senators to take a stand for children with juvenile arthritis. The Senate Appropriations Committee has proposed $5 million for the program and it’s a direct result of the work of Arthritis Foundation advocates, volunteers, and staff.
There are currently 300,000 children in America living with juvenile arthritis and less than 250 board-certified, practicing pediatric rheumatologists to care for them. If funded, this program will address a critical shortage by creating an incentive to pursue a career in pediatric rheumatology and placing well-trained providers in areas of need. To receive funding in FY 2014, the House of Representatives must also include funding in their proposed FY 2014 spending bill, which the House is currently drafting. Click here to send a pre-drafted message to your Representative requesting their support for the Pediatric Subspecialty Loan Repayment Program.
Arthritis Foundation DC Staff Walks on the Mall!
Several staff members of the Public Health Policy and Advocacy attended the Washington, DC Arthritis Walk on Saturday, May 18th. Laura Keivel, Coordinator of Advocacy Operations, served as Advocacy Chair for the event. Staff members and volunteers collected e-advocate sign-ups and talked about what everyone can do to support arthritis advocacy. Participants of the DC Walk took in the sights on the National Mall as they completed their walk. To learn more about our issues and to let your voice be heard on Capitol Hill, click here!
Arthritis Foundation DC Staff Joins U.S. Surgeon General in Every Body Walk! Initiative
Members of the Arthritis Foundation Public Health Policy and Advocacy staff in Washington, DC joined Surgeon General Dr. Regina Benjamin in a walk around Capitol Hill on May 15. Dr. Benjamin is hosting a series of walks throughout the month of May to raise awareness of the good walking can do for overall wellness. Additionally, Dr. Benjamin is raising awareness for the need for more walkable communities.
The walk started off with some Zumba moves and concluded with light stretching. Guests included Miss District of Columbia, Miss District of Columbia Teen, Miss Maryland, Miss Maryland Teen, as well as many government workers, public interest groups, Capitol Hill staffers, and wellness professionals.
If you are in the DC area and want to join, please visit the Surgeon General’s website for more information. To get walking in your area, click here to learn more about the Arthritis Foundation’s Walk with Ease program.
Congressional Arthritis Caucus Co-Hosts Briefing on Capitol Hill
On May 9th, Kathy Gingrich Lubbers presented at a briefing called “The Value of Public-Private Partnerships in Advancing Treatment for Rheumatoid Arthritis”. The briefing was sponsored by the Congressional Arthritis Caucus, in partnership with the Arthritis Foundation, the Personalized Medicine Coalition, the American Society of Clinical Rheumatologists, and Crescendo Bioscience.
Congressional Arthritis Caucus co-chairs Rep. David McKinley (R-WV) and Rep. Anna Eshoo (D-CA) welcomed over 50 staffers and guests to the event and gave a few remarks.
Steve Hoffmann, the Scientific Program Manager at the Biomarkers Consortium spoke on advancements in RA treatment and how the public-private partnerships allow for breakthroughs to happen. Additionally, Dr. Max Hamburger, President, American Society of Rheumatologists gave a detailed talk on the effects of rheumatoid arthritis and how advances in biologics have made RA more manageable.
Kathy Lubbers spoke of her experiences with RA and how biologics have enhanced her life. Without them, she said, she may have very well been confined to a wheel chair. She also spoke of the importance of maintaining funding for essential programs at the National Institutes of Health that spearhead advances in RA treatments and medication. For more information, please visit our page on the Arthritis Foundation NIH policy priority.
For more information on the briefing and for any questions, please contact Kim Beer, Director, Advocacy at firstname.lastname@example.org
Arthritis Foundation Provides a Statement on the Sequester
The Arthritis Foundation urges the administration and congress to protect vital discretionary programs as it works to reduce the nation’s deficit. Click to read the statement.
Expensive, disease-altering biologics currently cost many patients with autoimmune arthritis thousands of dollars each month.
The Arthritis Foundation supports new bipartisan legislation introduced in the House of Representatives this week that will increase affordability of medications for more than seven million Americans, including 300,000 children, with rheumatoid arthritis (RA), and other inflammatory diseases. If passed, the Patients’ Access to Treatment Act of 2013 (H.R. 460), introduced by Rep. David B. McKinley (R-WV) and Rep. Lois Capps (D-Calif.), will limit cost-sharing requirements for medications placed in a specialty tier and make innovative and necessary medications more accessible by reducing excessive out-of-pocket expenses.
Because of increasing costs, many insurance plans have instituted a tiered payment system for medications, often labeled ‘generic,’ ‘preferred,’ and ‘non-preferred’ and each have a set cost-sharing amount. A fourth tier, known as ‘specialty tiers,’ utilizes high patient cost-sharing for certain expensive medications. Patients who receive specialty tier medications pay a percentage of the cost of the drug, instead of paying the fixed amount, which results in skyrocketing costs for a single medication.
Biologic medications, including arthritis disease-modifying therapies, are increasingly found in specialty tiers. The result is high out-of-pocket costs, ranging from hundreds to thousands of dollars a month for a single medication. Because of this financial burden, people with arthritis may stop taking their prescribed medication or skip doses because they simply cannot afford it - even with health insurance and a prescription drug plan. Because there are no generic alternatives to biologics, the specialty tier cost-sharing structure negatively impacts people that depend on biologics - people with RA, psoriatic arthritis and other forms of inflammatory arthritis.
“This practice is unacceptable and discriminates against patients with chronic conditions. Cost-sharing for prescription medications should not be so large as to restrict or interfere with people’s treatment,” says Amy Melnick, vice president of advocacy for the Arthritis Foundation and co-chair of the Coalition for Accessible Treatments. “The Arthritis Foundation is one of 18 members of the Coalition for Accessible Treatments which encourages patients and physicians to ask lawmakers to support and co-sponsor the Patients’ Access to Treatments Act of 2013.”
Arthritis Foundation President and CEO Dr. John H. Klippel joins HHS Secretary Kathleen Sebelius in support of changes to the government insurance programs that will make it easier for Americans with pre-existing conditions to get health insurance coverage. Changes announced today to the Pre-Existing Condition Insurance Program (PCIP) will offer more Americans with chronic conditions, like arthritis, access to affordable coverage. Created under the Affordable Care Act, the PCIP is for people who are unable to purchase coverage due to their medical conditions.
"The seriousness of arthritis makes it unacceptable for people with it, or any other chronic disease, to be denied access to care and medications they need for any period of time," says Klippel. "The Arthritis Foundation is pleased to collaborate with the Secretary and Administration in raising awareness about this program to help individuals without insurance and with pre-existing conditions."
For more information on PCIP, visit https://www.pcip.gov/ .
The Congressional Arthritis Caucus held it's inaugural event on May 13, 2011 in honor of Arthritis Awareness Month. The event, "A Step Against Arthritis" invited congressional staff and local volunteers to Capitol Hill to symbolically walk around the Capitol and raise awareness about the importance of movement in the prevention and treatment of arthritis. Prior to the walk, a brief press event was held where participants heard from Dr. Jack Klippel, CEO and President of the Arthritis Foundation, and author and television personality Christine Schwab. Special thanks to Representatives Myrick (R-NC) and Eshoo (D-CA) for hosting the event and for the many local advocates who came in community spirit.
Arthritis Foundation Urges the Inclusion of Arthritis in the National Prevention Strategy
On behalf of the Arthritis Foundation, Kimberly Beer provided public comment on April 12, 2011 before a meeting of the Advisory Group on Prevention, Health Promotion and Integrative and Public Health (Advisory Group), chaired by U.S. Surgeon General Regina Benjamin. During her testimony, Kimberly shared startling statistics about the prevalence of arthritis among Americans and how the pain of arthritis is often a strong barrier to the treatment of many chronic diseases. Her statement urged the Advisory Group to include arthritis when developing their National Prevention Strategy. Read her testimony.
Representatives Myrick (NC) and Schakowsky (IL) Receive Advocacy Leadership Awards
The Arthritis Foundation was excited to grant two Advocacy Leadership Awards during the 2011 Advocacy Summit to Representatives Sue Myrick (NC-9) and Jan Schakowsky (IL-9) for their commitment to ending arthritis. This prestigious award recognizes policymakers who have performed exceptional service in support of the Arthritis Foundation’s mission. Representative Myrick currently co-chairs the Congressional Arthritis Caucus with Representative Anna Eshoo (CA).
Pennsylvania Advocates Meet with Senator Casey
On Tuesday, November 9, 2010 Arthritis Advocates Donna Trigone and her daughter, Maria Lefchak met with Senator Casey and his chief of staff, Jim Brown, to discuss the Arthritis Prevention, Control and Cure Act. Maria and Donna stressed the importance of passing the Arthritis Act prior to the end of the 111th Congress and Senator Casey agreed to help. Thanks for fighting arthritis, Donna and Maria! To meet with your Members of Congress and learn more about the important work the Arthritis Foundation does in Washington, become an Arthritis Advocate today!
Sophia Rothman Raises Awareness About Juvenile Arthritis on Fox News
Senator Franken Speaks Out in Support of the Arthritis Prevention, Control and Cure Act
Arthritis Ambassadors Visiting with their Members of Congress During the 2010 August Recess
Young Advocate Mikayla Minning Dines with Rep. Roybal-Allard and Talks Policy
August 13, 2010. The words "August Recess" may remind of you of a time gone by, running through sprinklers and dreading each day that signaled the approach of a new school year, but for our members of Congress August Recess is no day in the sun. It's a month for members to return to their home district and meet with the constituents they serve (Learn more about the history of August Recess). This August Recess the Arthritis Foundation has encouraged our Arthritis Ambassadors to meet with their members of Congress and talk with them about our legislative priorities. With over 50 meetings on the books, our advocates are working hard to make sure that when Congress reconvenes "arthritis" is on the lips of everyone in the House and Senate. Carrying out her August Ambassador assignment, Mikayla Minnig of California asked Congresswoman Lucille Roybal-Allard, a cosponsor of the Arthritis Prevention, Control and Cure Act, for a minute of her time. Rep. Roybal-Allard generously spent two hours with Mikayla at lunch where they discussed the state of Mikayla's arthritis, her experience at JA Camp, the rising cost of medications for children with arthritis, and the importance of passing the Arthritis Act. Thanks to Representative Roybal-Allard for taking the time to meet with the Minnig family and a special thanks to our brave arthritis advocate, Mikayla Minnig, for working hard to develop and maintain a strong, growing relationship with your member of Congress! Learn more about the Arthritis Ambassador Program.
Pacific Northwest Recruits New Advocates at 9th Annual Symposium
Ambassador Peg Timmins of Sammamish, WA collects Dear Senator letters from e-advocate and Arthritis Foundation Aquatic Program leader Shirley Rancich of Mountlake Terrace, WA at the Pacific Northwest Chapter’s 9th Annual Symposium on Arthritis.
Lt. Governor Aiona Joins the Hawai'i Arthritis Walk
In an effort to raise funds and awareness about arthritis, Hawai'i's Lt. Governor Duke Aiona participated in the state's 2010 Arthritis Walk. "Through donations and support, the Arthritis Foundation continues to serve our community by providing exercise programs led by certified instructors who help people exercise safely to treat their arthritis and better manage their pain," Lt. Governor Aiona said. There are currently 236,000 people in Hawai'i living with arthritis. Thanks for joining the fight against arthritis, Governor Aiona! To learn to learn arthritis-related statistics for your state, click here.
Arthritis Ambassador Mike O'Toole Takes Connecticut Walks By Storm!
Advocacy Shines at the Arthritis Walk in Evansville, Indiana
Great advocates come in every age and form. It was cold and windy at the May 8th Evansville, Indiana Arthritis Walk this year, but that didn’t stop Congressman Brad Ellsworth (IN-8) from coming out and enjoying the festivities. Rep. Ellsworth kicked-off the walk with a heart-warming speech and even stopped to ask the 2010 Young Hero, Payton Pierce, for her signature. He has set the autographed photo on his desk in Washington to serve as a constant reminder of what he has been elected to do while serving in office. Thanks to both Rep. Ellsworth and Payton for fighting arthritis at home, in your communities and in Washington! To join them and fight arthritis through advocacy, sign up as an arthritis e-advocate today.
Arthritis Advocate Makes Today Show Appearance
Mr. Lee Evans of New York, New York joined Arthritis Foundation staff on May 6, 2010 to appear on the Today Show. Lee learned about the opportunity to participate in the screening through an e-alert sent out to advocates living in the NYC area. Despite walking with a cane, Lee joined the team at 6 AM and stayed for several hours - all in the name of arthritis awareness. Thanks for moving to make a difference, Lee!